NUCLEOTIDE SEQUENCES OF MORAXELLA CATARRHALIS GENOME

Abstract: The present invention provides the genomic sequences of a library of purified nucleic acid molecules, or their complements, comprising the genome of <u>Moraxella catarrhalis</u>. The invention also provides the identification of open reading frames contained within the nucleic acid molecules of the library. The present invention further provides for the use of the nucleic acid molecules, their complements or fragments, and proteins or portions thereof for identifying ligands and useful diagnostic and therapeutic compositions. In addition the invention provides for vectors, host cells and methods for producing <u>M-catarrhalis</u> proteins or portions thereof.

Description: NUCLEOTIDE SEQUENCES OF MORAXELLA CATARRHALIS GENOME A portion of the disclosure of mis patent document contains material which is subject to copyright protection. The copyright owner has no objection to the facsimile reproduction by anyone of the patent document or the patent disclosure, as it appears in the Patent and Trademark Office patent file or records, but otherwise reserves all copyright rights whatsoever. TECHNICAL FIELD The present invention discloses nucleotide sequences from the genome of Moraxella catarrhalis. These sequences may be used in various assays and in the development of diagnostic and therapeutic agents. BACKGROUND OF INVENTION All animals coexist with an indigenous microflora. Beginning shortly after birth, the gastrointestinal tract, lungs, and other areas of the human body are colonized by different bacterial species. A large number of factors operate to maintain symbiotic, host-microbe balance. These include the physical barriers of skin and mucosal surfaces and both nonspecific and highly specific aspects of the immune system. When host- microbe balance becomes disturbed, infection may ensue. Virulence, the ability of a microbe to produce infection, is related to a variety of complex mechanisms of disease induction. Some organisms are highly virulent and cause clinical illness when they colonize most or all hosts. Alternatively, when host defenses are compromised, normally symbiotic microbes can induce serious, or even life-threatening, infections. Thus, infection is generally a consequence of the interaction between a relatively virulent microbe and a normal host or between a relatively less virulent microbe and a host with some degree of transient or permanent immunological impairment. M. catarrhalis (Branhamella catarrhalis) is a large, aerobic, gram-negative diplococcus normally found among the bacterial flora of human upper airways. It is nonmotile and possesses fimbriae. Collonies are regularly friable and nonadherent and grow well on blood or chocolate agar. Unlike many other pathogenic bacteria, M. catarrhalis shows a high degree of homogeneity in its outer membrane proteins. This usually harmless parasite of the mucous membranes may behave as an opportunistic pathogen when microbe-host balance is perturbed. Following infection, host antibodies directed against one or more of the microbial outer-membrane proteins are detectable in the serum. M- catarrhalis is known to cause acute, localized infections such as otitis media, sinusitis, and bronchopulmonary infection and life-threatening, systemic diseases including endocarditis and meningitis. The presence of bacterial endotoxin and host histamine and chemotactic factors are major indicators of M. cataπhalis pathogenicity. M. catarrhalis can be isolated from the upper respiratory tract of 50% of healthy school children and 7% of healthy adults. In children with otitis media, colonization increases to 86%, and it is the third most common bacterial isolate. It causes 10-15% of otitis media and sinusitis. Infections of the maxillary sinuses, middle ears, or bronchi may occur through contiguous spread of the microbes. M. catarrhalis causes a large proportion of lower respiratory tract infections in elderly patients with chronic obstructive pulmonary diseases and is exceeded only by Haemophilus influenzae and Streptococcus pneumoniae as a causative agent of acute purulent exacerbations of chronic bronchitis. Pneumonia due to M. catarrhalis, like that of H. influenzae or S. pneumoniae, begins with aspiration of the bacteria. Failure or absence of appropriate host defense allows the bacteria to replicate and produce an inflammatory response in the alveoli. Because of mandatory immunosuppression, organ transplant recipients can develop moderate to severe M. catarrhalis pneumonia very rapidly. Bloodstream invasion is less characteristic of M. catarrhalis than pneumococcal infection, but nearly 50% of M. catarrhalis pneumonia patients die within 3 months of onset. M. catarrhalis is treated with antibiotic agents including penicillin-clavulanic acid combinations, cephalosporins, tetracycline, erythromycin, chloramphenicol, trimethoprim-sulfamethoxazole, and quinolones. Over 85% of M. catarrhalis clinical isolates have been reported to be resistant to penicillin. Moreover, the microbe protects itself by binding to the first subcomponent of the complement system (Clq) which inactivates the Cl complex or by inactivating the terminal, lytic complement complex via a protein on the outer cell wall surface. Resistance is mediated by two closely related β-lactamases, BRO-1 , present in 90% of resistant isolates and BRO-2, present in 10%. These enzymes are active against penicillin, ampicillin, and amoxicillin, less active against cephalosporins, and bind avidly to clavulanic acid and sublactam. Tetracycline resistant strains are increasing in Europe and Asia and have been documented in the United States. Ampicillin, which had been universally effective in treating M. catarrhalis pneumonia, can no longer be used. M. catarrhalis physiology and pathogenicity are reviewed in: Holt et al. (1994) Bergev's Manual of Determinative Bacteriology. Williams and Wilkins, Baltimore MD; Cullmann (1997) Med Klin 92(3):162- 166; Isselbacher et al. (1994) Harrison's Principles of Internal Medicine, McGraw-Hill, New York NY; Murray (1995) Manual of Clinical Microbiology. ASM Press, Washington DC; and Shulman et al. (1997) The Biologic and Clinical Basis of Infectious Diseases. WB Saunders, Philadelphia PA. In view of the conditions or diseases associated with M. catarrhalis. it would be advantageous to provide specific methods for the diagnosis, prevention, and treatment of diseases attributed to M. catarrhalis. Relevant methods would be based on the expression of M. catarrhalis-derived nucleic acid sequences. Such traits as virulence, acquisition of resistance factors, and effects of treatment using particular therapeutic agents may be characterized by under- or over-expression of nucleic acid sequences as revealed using PCR, hybridization or microarray technologies. Treatment for diseases attributed to M. catarrhalis can then be based on expression of these identified sequences or their expressed proteins, and efficacy of any particular therapy and development of resistance monitored. The information provided herein provides the basis for understanding the pathogenicity of M. catarrhalis and treating and monitoring the treatment of diseases caused by M. catarrhalis. SUMMARY OF THE INVENTION The present invention relates to a genomic library comprising the combination of nucleic acid molecules from Moraxella catarrhalis, presented as SEQ ID NOs: 1-41. The library substantially provides the nucleic acid molecules comprising the genome of M. catarrhalis. and the nucleic acid molecules provide a plurality of open reading frames (ORFs). The ORFs uniquely identify structural, functional, and regulatory genes of M. catarrhalis. The invention encompasses oligonucleotides, fragments, and derivatives of the M. catarrhalis nucleic acid molecules, and sequences complementary to the nucleic acid molecules listed in the Sequence Listing. M. catarrhalis nucleic acid molecules, fragments, derivatives, oligonucleotides, and complementary sequences thereof, can be used as probes to detect, amplify, or quantify M. catarrhalis genes, ORFs, cDNAs, or RNAs in biological, solution or substrate-based, assays or as compositions in diagnostic kits. The invention contemplates the use of such diagnostic probes to identify the presence of M. catarrhalis sequence in a sample or to screen for virulence factors and mutations. The invention also provides for the comparison of the M. catarrhalis genomic library or the encoded proteins with genomes, individual DNA sequences, or proteins from other Moraxella species or strains, other bacteria, and other organisms to identify virulence factors, regulatory elements, drug targets, and to characterize genomic organization. In another aspect, the present invention provides for the use of computer databases to make such comparisons. The invention further provides host cells and expression vectors comprising nucleic acid molecules of the invention and methods for the production of the proteins they encode. Such methods include culturing the host cells under conditions for expression of M. catarrhalis protein and recovering the protein from cell culture. The invention still further provides purified M. catarrhalis protein of which at least a portion is encoded by a nucleic acid molecule selected from the nucleic acid molecules of the Sequence Listing. The subject invention provides a method of screening a library or a plurality of molecules or compounds for specific binding to a M. catarrhalis nucleic acid molecule or fragment thereof or protein or portion thereof, to identify at least one ligand which specifically binds the M. catarrhalis nucleic acid molecule or protein. Such a method comprises the steps of combining the M. catarrhalis nucleic acid molecule or protein with a library or a plurality of molecules or compounds under conditions to allow specific binding and detecting M. catarrhalis nucleic acid molecule or protein bound to at least one molecule or compound, thereby identifying a ligand which specifically binds the nucleic acid molecule or protein. Suitable libraries of ligands comprise aptamers, DNA molecules, RNA molecules, peptide nucleic acids, peptides, mimetics, proteins, agonists, antagonists, antibodies, inhibitors, immunoglobulins, pharmaceutical agents, and drug compounds. The subject invention also provides a method of purifying a ligand from a sample. Such a method comprises the steps of combining the M. catarrhalis nucleic acid molecule or protein with a library or a plurality of molecules or compounds under conditions to allow specific binding, detecting M. catarrhalis nucleic acid molecule or protein bound to at least one molecule or compound, recovering the bound M. catarrhalis nucleic acid molecule or protein and separating the bound M. catarrhalis nucleic acid molecule or protein from the ligand, thereby obtaining purified ligand. The invention further comprises an antibody specific for a purified M. catarrhalis protein or a portion thereof which is encoded by an M. catarrhalis nucleic acid molecule selected from the Sequence Listing. Antibodies produced against M. catarrhalis protein may be used diagnostically for the detection of M. catarrhalis proteins in biological, solution- or substrate-based, samples and therapeutically to neutralize the activity of an M. catarrhalis protein expressed during infections caused by M. catarrhalis. DESCRIPTION OF THE SEQUENCE LISTING AND TABLES The Sequence Listing is a compilation of the consensus sequences of contiguous sequences (contigs) or groups of overlapping sequences, assembled from individual sequences obtained by sequencing genomic clone inserts of a randomly generated M. catarrhalis DNA library. Each assembled contig or singlet is identified by a sequence identification number (SEQ ID NO) and by the contig number which it represents. Table 1 lists the assembled M. catarrhalis contiguous sequences prepared as described in the Examples. The first column contains the number of the contig, which is also SEQ ID NO, listed in ascending order. The second column contains the length of the nucleic acid molecule. The third and fourth columns contain the start and stop nucleotides, respectively, for any open reading frames (ORFs) in the contig. The fifth column contains the Locus ID. The sixth column lists the GenBank identification number of the closest homolog, if any. The seventh column gives the P- value for the match to the homolog. The last column contains the description of the homolog. Orphans or LURs have no GenBank homologs. Table 2 shows the order of the contigs or singlets comprising the M- catarrhalis genome. DESCRIPTION OF THE PREFERRED EMBODIMENTS It is understood that this invention is not limited to the particular machines, materials and methods described. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the scope of the present invention which will be limited only by the appended claims. As used herein, the singular forms "a", "an", and "the" include plural reference unless the context clearly dictates otherwise. For example, a reference to "a host cell" includes a plurality of such host cells known to those skilled in the art. All patents and publications cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which might be used in connection with the invention are expressly incorporated by reference. Citation is for the purpose of providing the best description of the invention and is not to be construed as an admission that the invention is not entitled to antedate such disclosure. Definitions "Biologically active" refers to a protein having structural, immunological, regulatory, or chemical functions of a naturally occurring, recombinant, or synthetic molecule. "Complementary" refer to the natural hydrogen bonding by base pairing between purines and pyrimidines. For example, the sequence A-C-G-T forms hydrogen bonds with its complements T-G-C-A or U-G-C-A The degree of complementarity between nucleic acid strands affects the efficiency and strength of the hybridization and amplification reactions. "Derivative" refers to the chemical modification of a nucleic acid or amino acid molecule. Chemical modifications can include replacement of hydrogen by an alkyl, acyl, or amino group or glycosylation, pegylation, or any similar process which retains or enhances biological activity, stability, or lifespan of the molecule. "Fragment" refers to an Incyte clone or any part of a nucleic acid molecule which retains a usable, functional characteristic. Useful fragments include oligonucleotides which may be used in hybridization or amplification technologies or to regulate replication, transcription or translation. "Hybridization complex" refers to a complex between two nucleic acid molecules by virtue of the formation of hydrogen bonds between purines and pyrimidines. "Ligand" refers to any molecule or compound which will bind to a complementary site on a nucleic acid molecule or protein. "Modulates" refers to a change in activity (biological, chemical, or immunological) or lifespan resulting from specific binding between a molecule or compound and either a nucleic acid molecule or a protein. "Molecules" is used substantially interchangeably with the terms agents and compounds. Such molecules modulate the activity of nucleic acid molecules or proteins of the invention and may be composed of at least one of the following: inorganic and organic substances including cofactors, nucleic acids, proteins, carbohydrates, fats, and lipids. "Nucleic acid molecule" is substantially interchangeable with the term polynucleotide and may refer to a probe, a fragment of DNA or RNA of genomic or synthetic origin. Such molecules may be double-stranded or single-stranded and may be engineered into vectors to perform a particular activity such as transcription. "Oligonucleotide" is substantially equivalent to the terms "amplimer", "primer", "oligomer", and "element", and is preferably single stranded. "Protein" refers to an amino acid sequence, oligopeptide, peptide, polypeptide or portions thereof whether naturally occurring or synthetic. "Portion"refers to any part of a protein used for any purpose, but especially for the screening of a library of molecules or compounds which specifically bind to that portion or for the production of antibodies. "Sample" is used in its broadest sense. A sample containing nucleic acid molecules may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; genomic DNA, RNA, or cDNA in solution or bound to a substrate; a cell; a tissue; a tissue print; a hair, and the like. "Substantially purified" refers to nucleic acid molecules or proteins that are isolated or separated from their natural environment and are about 60% free to about 90% free from other components with which they are naturally associated. "Substrate" refers to any rigid or semi-rigid support to which nucleic acid molecules or proteins are bound and includes membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, capillaries or other tubing, plates, polymers, and microparticles with a variety of surface forms including wells, trenches, pins, channels and pores. THE INVENTION The majority of the Moraxella catarrhalis genome was sequenced using a strategy of shotgun sequencing. Genomic DNA was mechanically sheared, treated with enzyme to create blunt ends, gel- purified, and cloned into modified PBLUESCRIPT vectors (Stratagene, La Jolla CA). The vectors were transformed into E. coli cells and grown overnight. Colonies were picked, and plasmid DNA was isolated. Templates were prepared and sequenced, sequences were assembled into contiguous sequences (contigs), and open reading frames were identified. The invention relates to a Moraxella catarrhalis genomic DNA library comprising a combination of nucleic acid molecules, SEQ ID NOs:l-41, and their complements. These nucleic acid molecules comprise contiguous sequences which contain annotated and unannotated reading frames (ORFs and LURs). The nucleic acid molecules or fragments and probes thereof are used in hybridization, screening, and purification assays to identify ligands and in vectors and host cells to produce the proteins which they encode. The proteins or portions thereof are also used in screening and purification assays to identify useful ligands or to produce antibodies. The molecules or compounds used in hybridization, screening, and purification assays include aptamers, DNA molecules, RNA molecules, peptide nucleic acids, peptides, mimetics, transcription factor, enhancers, repressors, regulatory proteins, agonists, antagonists, antibodies, inhibitors, immunoglobuhns, pharmaceutical agents, drug compounds, and the like. The nucleic acid molecules and proteins of M- catarrhalis are compared with those of other organisms using computer algorithms and databases to select those nucleic acid molecules and proteins of potential diagnostic and therapeutic use. Characterization and Use of the Invention Sequencing Methods for sequencing nucleic acid molecules are well known in the art and may be used to practice any of the embodiments of the invention. These methods employ enzymes such as the Klenow fragment of DNA polymerase I, SEQUENASE, Taq DNA polymerase, thermostable T7 DNA polymerase (Amersham Pharmacia Biotech (APB), Piscataway NJ), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system QLJfe Technologies, Rockville MD). Preferably, sequence preparation is automated with machines such as the HYDRA microdispenser (Robbins Scientific, Sunnyvale CA), MICROLAB 2200 system (Hamilton, Reno NV), and the DNA ENGINE thermal cycler (MJ Research, Watertown MA). Machines used for sequencing include the ABI 3700, 377 or 373 DNA sequencing systems (PE Biosystems, Foster City CA), the MEGABACE 1000 DNA sequencing system (APB), and the like. The sequences may be analyzed using a variety of algorithms which are well known in the art and described in Ausubel (1997; Short Protocols in Molecular Biology. John Wiley & Sons, New York NY, unit 7.7) and in Meyers (1995; Molecular Biology and Biotechnology. Wiley VCH, New York NY, pp. 856-853). Shotgun sequencing methods are well known in the art and use thermostable DNA polymerases and heat-labile DNA polymerases. A detailed procedure is provided in the Examples. Prefinished sequences (incomplete assembled sequences) are cross-compared for identity using various algorithms or programs such as CONSED (Gordon (1998) Genome Res. 8:195-202), GELVTEW Fragment Assembly system (Genetics Computer Group, Madison WI, and PHRAP (Phil Green, University of Washington, Seattle WA). Contaminating sequences, including vector or chimeric sequences, can be masked, removed or restored, in the process of turning the prefinished sequences into finished sequences. Extension of a Nucleic Acid Sequence The sequences of the invention may be extended using various PCR-based methods known in the art. For example, the XL-PCR kit (PE Biosystems), nested primers, and commercially available cDNA or genomic DNA libraries (Life Technologies and Clontech (Palo Alto CA), respectively) may be used to extend the nucleic acid sequence. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 software (National Biosciences, Plymouth MN) to be about 22 to 30 nucleotides in length, to have a GC content from about 40-45%, and to anneal to a target molecule at temperatures from about 55C to about 68C. When extending a sequence to recover untranslated, regulatory elements, it is preferable to use genomic, rather than cDNA libraries. Use of M. Catarrhalis Nucleic Acid Molecules Hybridization The M. catarrhalis nucleic acid molecules and fragments thereof can be used in various hybridization technologies for various purposes. Hybridization probes may be designed or derived from a highly unique region such as the 5' untranslated sequence preceding the initiation codon or from a conserved coding region encoding a specific protein signature or motif and used in protocols to identify naturally occurring molecules encoding a particular M. catarrhalis protein, allelic variants, or related molecules. The probe should preferably have at least 50% sequence identity to any naturally occurring nucleic acid sequences. The probe may be a single stranded DNA or RNA molecule, produced biologically or synthetically, and labeled using oligolabeling, nick translation, end-labeling, or PCR amplification in the presence of at least one labeled nucleotide. A vector containing the nucleic acid molecule or a fragment thereof may be used to produce an mRNA probe in vitro by addition of an RNA polymerase and labeled nucleotides. These procedures may be conducted using commercially available kits such as those provided by APB. The stringency of hybridization is determined by G+C content of the probe, salt concentration, and temperature. In particular, stringency can be increased by reducing the concentration of salt or raising the hybridization temperature. In solutions used for some membrane based hybridizations, addition of an organic solvent such as formamide allows the reaction to occur at a lower temperature. Hybridization can be performed at low stringency with buffers, such as 5xSSC with 1 % sodium dodecyl sulfate (SDS) at 60C, which permits the formation of a hybridization complex between nucleic acid sequences that contain some mismatches. Subsequent washes are performed at increased stringency with buffers such as 0.2xSSC with 0.1% SDS at either 45C (medium stringency) or 68C (high stringency). At high stringency, hybridization complexes will remain stable only where the nucleic acid molecules are completely complementary. In some membrane-based hybridizations, 35-50% formamide can be added to the hybridization solution to reduce the temperature at which hybridization is performed. Background signals can be reduced by the use of other detergents such as Sarkosyl or TRITON X-100 (Sigma-Aldrich, St. Louis MO) and a blocking agent such as denatured salmon sperm DNA. Selection of components and conditions for hybridization are well known to those skilled in the art and are reviewed in Ausubel (supra) and in Sambrook et al. (1989; Molecular Cloning, A Laboratory Manual. Cold Spring Harbor Press, Plainview NY). Microarrays may be prepared and analyzed using methods known in the art. Oligonucleotides or fragments of a nucleic acid molecule may be used as either probes or targets. The microarray can be used to monitor the expression level of large numbers of genes simultaneously and to identify genetic variants, mutations, and single nucleotide polymorphisms. Such information may be used to determine gene function; to understand the genetic basis of a condition, disease, or disorder; to diagnose a condition, disease, or disorder; and to develop and monitor the activities of therapeutic agents used to treat the condition, disease, or disorder. (See, eg, Brennan et al. (1995) USPN 5,474,796; Schena et al. (1996) Proc Natl Acad Sci 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon et al. (1995) PCT application WO95/35505; Heller et al. (1997) Proc Natl Acad Sci 94:2150-2155; and Heller et al. (1997) USPN 5,605,662.) Hybridization probes are also useful in mapping the naturally occurring genomic sequence. The probes may be hybridized to: 1) a particular chromosome, 2) a specific region of a chromosome, 3) an artificial chromosome constructions such as human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial PI constructions, single chromosomes from eukaryotic species, or 5) DNA libraries made from any of these sources. Expression A nucleic acid molecule encoding a M. catarrhalis protein may be cloned into a vector and used to express the protein or portions thereof in host cells. The nucleic acid sequence can be engineered by such methods as DNA shuffling (USPN 5,830,721) and site-directed mutagenesis to create new restriction sites, alter glycosylation patterns, change codon preference to increase expression in a particular host, produce splice variants, extend half-life, and the like. The expression vector may contain transcriptional and translational control elements ( romoters, enhancers, specific initiation signals, and polyadenylated sequence) from various sources which have been selected for their efficiency in a particular host. The vector, nucleic acid molecule, and regulatory elements are combined using in vitro recombinant DNA techniques, synthetic techniques, and/or in vivo genetic recombination techniques well known in the art and described in Sambrook (supra, ch. 4, 8, 16 and 17). A variety of host systems may be transformed with an expression vector. These include, but are not limited to, bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems transformed with baculovirus expression vectors; plant cell systems transformed with expression vectors containing viral and/or bacterial elements, or animal cell systems (Ausubel, supra, unit 16). Routine cloning, subcloning, and propagation of nucleic acid molecules can be achieved using the multifunctional PBLUESCRIPT vector (Stratagene) or PSPORT1 plasmid (Life Technologies). Introduction of a nucleic acid sequence into the multiple cloning site of these vectors disrupts the lacZ gene and allows colorimetric screening for transformed bacteria. In addition, these vectors may be useful for in vitro transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. For long term production of recombinant M. catarrhalis proteins, the vector can be stably transformed into competent cells of E. coli along with a selectable or visible marker gene on the same or on a separate vector. After transformation, cells are allowed to grow in enriched media containing a selective agent. Selectable markers, antimetabolite, antibiotic, or herbicide resistance genes confer resistance to the respective selective agent and allow growth and recovery of cells which successfully express the introduced sequences. Resistant clones or colonies, identified either by survival on selective media or by the expression of visible markers, such as anthocyanins, green fluorescent protein (GFP), β glucuronidase, luciferase and the like, may be propagated using culture techniques well known in the art. Visible markers are also used to quantify d e amount of protein expressed by the introduced genes. Verification that the host cell contains the desired M. catarrhalis nucleic acid molecule is based on DNA-DNA or DNA-RNA hybridizations or PCR amplification. The host cell may be chosen for its ability to modify a recombinant protein in a desired fashion. Such modifications include acetylation, carboxylation, glycosylation, phosphorylation, lipidation, acylation, and the like. Post-translational processing sequences ("prepro" forms) may also be engineered into the recombinant nucleotide sequence in order to specify protein targeting, folding, and/or activity. Different host cells available from the ATCC (Manassas VA) which have specific cellular machinery and characteristic mechanisms for post-translational activities may be chosen to ensure the correct modification and processing of the recombinant protein. Recovery of Proteins from Cell Culture Heterologous moieties engineered into a vector for ease of purification include glutathione S- transferase (GST), calmodulin binding peptide (CBP), 6xHis, FLAG, MYC, and the like. GST, CBP, and 6xHis are purified using commercially available affinity matrices such as immobilized glutathione, calmodulin, and metal-chelate resins, respectively. FLAG and MYC are purified using commercially available monoclonal and polyclonal antibodies. A proteolytic cleavage site may be located between d e desired protein sequence and the heterologous moiety for ease of separating the desired protein following purificatioa Methods for recombinant protein expression and purification are discussed in Ausubel (supra, unit 16) and are commercially available (Invitrogen, San Diego CA). Chemical Synthesis of Peptides Proteins or portions thereof may be produced not only by recombinant methods, but also by using chemical methods well known in the art. Solid phase peptide synthesis may be carried out in a batchwise or continuous flow process which sequentially adds α-amino and side chain-protected amino acid residues to an insoluble polymeric support via a Unker group. A Unker group such as methylamine-derivatized polyethylene glycol is attached to poly(styrene-co-divinylbenzene) to form the support resin. The amino acid residues are N-α-protected by acid labile Boc (t-butyloxycarbonyl) or base-labile Fmoc (9-fluorenylmethoxycarbonyl). The carboxyl group of the protected amino acid is coupled to the amine of the Unker group to anchor the residue to the solid phase support resin. Trifluoroacetic acid or piperidine are used to remove the protecting group in the case of Boc or Fmoc, respectively. Each additional amino acid is added to the anchored residue using a coupling agent or pre-activated amino acid derivative, and the resin is • washed. The full length peptide is synthesized by sequential deprotection, coupling of derivitized amino acids, and washing with dichloromethane and/or N, N-dimethylformamide. The peptide is cleaved between the peptide carboxy terminus and the Unker group to yield a peptide acid or amide. (Novabiochem 1997/98 Catalog and Peptide Synthesis Handbook, San Diego CA, pp. S1-S20). Automated synthesis may also be carried out on machines such as the ABI 431 A peptide synthesizer (PE Biosystems). A protein or portion thereof may be substantially purified by preparative high performance Uquid chromatography and its composition confirmed by amino acid analysis or by sequencing (Creighton (1984) Proteins. Structures and Molecular Properties. WH Freeman, New York NY). Preparation and Screening of Antibodies Various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with M. catarrhalis protein or any portion thereof. Adjuvants such as Freund's, mineral gels, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemacyanin (KLH), and dinitrophenol may be used to increase immunological response. The oUgopeptide, peptide, or portion of protein used to induce antibodies should consist of about five to fifteen amino acids which are identical to a portion of the natural protein. OUgonucleotides may be fused with proteins such as KLH in order to produce antibodies to die chimeric molecule. Monoclonal antibodies may be prepared using any technique which provides for the production of antibodies by continuous cell Unes in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, eg, Kohler et al. (1975) Nature 256:495-497; Kozbor et al. (1985) J Immunol Methods 81 :31-42; Cote et al. (1983) Proc Natl Acad Sci 80:2026-2030; and Cole et al. (1984) Mol Cell Biol 62:109-120.) Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce epitope specific single chain antibodies. Antibody fragments which contain specific binding sites for epitopes of the M. catarrhahs protein may also be generated. For example, such fragments include, but are not Umited to, F(ab')2 fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab')2 fragments. Alternatively, Fab expression Ubraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity (Huse et al. (1989) Science 246:1275-1281). The M. catarrhaUs protein may be used in screening assays of phagemid or B-lymphocyte immunoglobulin libraries to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoassays using either polyclonal or monoclonal antibodies with estabUshed specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between the protein and its specific antibody. A two-site, monoclonal-based immunoassay utiUzing monoclonal antibodies reactive to two non-interfering epitopes is preferred, but a competitive binding assay may also be employed (Pound (1998) Immunochemical Protocols, Humana Press, Totowa NJ). LabeUng of Molecules for Assay A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid molecule, protein, and antibody assays. Synthesis of labeled molecules may be achieved using Promega (Madison WI) or APB kits for incorporation of a labeled nucleotide such as 32 P- dCTP, Cy3-dCTP or Cy5-dCTP (APB) or amino acid such as 35 S-methionine (APB). Nucleotides and amino acids may be directly labeled with a variety of substances including fluorescent, chemiluminescent, or chromogenic agents and die Uke, by chemical conjugation to amines, thiols and other groups present in the molecules using reagents such as BIODIPY or FITC (Molecular Probes, Eugene OR). Diagnostics The nucleic acid molecules, fragments, oUgonucleotides, complementary RNA and DNA molecules, and peptide nucleic acids (PNAs) may be used to detect and quantify differential gene expression, absence/presence vs. excess, of mRNAs or to monitor mRNA levels following drug treatment. Conditions, diseases or disorders associated with M. cataπhahs gene expression may include conditions and diseases such as allergies, asthma, bronchitis, chronic obstructive pulmonary disease, emphysema, endocarditis, hypereosinophiUa, meningitis, otitis media, pneumonia, sinusitis, and various respiratory distress syndromes. The diagnostic assay may use hybridization or ampUfication technology to compare gene expression in a biological sample from a patient to expression in disease and control standards in order to detect differential gene expression. QuaUtative or quantitative methods for this comparison are well known in the art. For example, the nucleic acid molecule, fragment, or probe may be labeled by standard methods and added to a sample from a patient under conditions for the formation of hybridization complexes. After an incubation period, the sample is washed and the amount of label (or signal) associated with hybridization complexes, is quantified and compared with a standard value. If the amount of label in the patient sample is significantly altered in comparison to the standard value, then the presence of elevated amounts of M. catarrhalis is responsible for the associated condition or disease. In order to provide a basis for the diagnosis of a condition, disease or disorder associated with gene expression, a normal or standard expression profile is estabUshed. This may be accompUshed by combining a biological sample taken from normal subjects, animal or more preferably human, with a probe under conditions for hybridization or ampUfication. Standard hybridization may be quantified by comparing the values obtained using normal subjects with values from an experiment in which a known amount of a substantially purified target sequence is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a particular condition or diseases Usted above. Deviation from standard values toward those associated with a particular diagnosed condition is used to diagnose the patient. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies or in a cUnical trial. Once efficacy is estabUshed, these assays may be used on a regular basis to determine if the therapy is effective in an individual patient. The results obtained from successive patient assays may be used over a period ranging from several days to months. Immunological Methods Detection and quantification of a protein using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-Unked immunosorbent assays (ELISAs), radioimmunoassays, and fluorescence activated cell sorting. A two-site, monoclonal-based immunoassay utiUzing monoclonal antibodies reactive to two non-interfering epitopes is preferred, but a competitive binding assay may be employed. (See, eg, CoUgan et al. (1997) Current Protocols in Immunology, Wiley- Interscience, New York NY; Pound, supra.) Therapeutics Chemical and structural similarity, in the context of sequences, signatures and motifs, antigenic epitopes and the like, generally exists between regions of homologous proteins. Comparisons of M. catarrhalis nucleic acid molecules and proteins with those of other M. catarrhalis strains, other bacteria and other organisms allow preselection of therapeutic agents that affect the pathogenic organism without harming the host. Such therapeutic agents are useful in treating conditions and diseases such as allergies, asthma, bronchitis, chronic obstructive pulmonary disease, emphysema, endocarditis, hypereosinophiUa, meningitis, otitis media, pneumonia, sinusitis, and various respiratory distress syndromes caused by M. catarrhalis. In conditions associated with increased expression or activity of M. catarrhaUs nucleic acid molecule or protein, it is desirable to decrease expression or protein activity. In one embodiment, a Ugand such as an antagonist, antibody, or inhibitor identified by screening a pluraUty of molecules with the M. catarrhaUs protein is admimstered to d e subject to decrease the activity of the M. catarrhalis or homologous protein as it is overexpressed during pathogenesis. In another embodiment, a composition comprising the substantially purified ligand and a pharmaceutical carrier may be administered to a subject to decrease d e activity of the M. catarrhaUs or homologous protein as it is overexpressed during pathogenesis. In one aspect, an antibody which specifically binds the M. catanhahs protein may be used as a targeting or deUvery mechanism for bringing a pharmaceutical agent to cells or tissues which are affected by the overexpression of the M. catarrhalis protein. Any of the ligands may be administered in combination with other therapeutic agents. Selection of the agents for use in combination therapy may be made by one of ordinary skill in the art according to conventional pharmaceutical principles. A combination of therapeutic agents may act synergistically to effect prevention or treatment of a particular condition at a lower dosage of each agent. Modification of Gene Expression Using Nucleic Acids Gene expression may be modified by designing complementary or antisense molecules (DNA, RNA, or PNA) to the 5 ', 3 ', or intronic regions of the M. catanhaUs nucleic acid molecule. OUgonucleotides designed with reference to the transcription initiation site are prefened. Similarly, inhibition can be achieved using triple heUx base-pairing which inhibits the binding of polymerases, transcription factors, or regulatory molecules (Gee et al. In: Huber and Can (1994) Molecular and Immunologic Approaches. Futura Publishing, Mt. Kisco NY, pp. 163-177). A complementary molecule may also be designed to block translation by preventing binding between ribosomes and mRNA. In one alternative, a Ubrary of cDNA molecules may be screened to identify those which specifically bind a regulatory, untranslated M. catanhaUs sequence. DeUvery of this inhibitory nucleotide sequence using a vector designed to be transfened from transformed M. catanhaUs cells to infectious M. catanhalis via genetic recombination is contemplated. Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of an M. catanhaUs RN The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA followed by endonucleolytic cleavage at sites such as GUA, GUU, and GUC. Once such sites are identified, an oUgonucleotide with the same sequence may be evaluated for secondary structural features which would render the oUgonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing their hybridization with complementary oUgonucleotides using ribonuclease protection assays. Complementary nucleic acids and ribozymes of the invention may be prepared via recombinant expression, in vitro or in vivo, or using soUd phase phosphoramidite chemical synthesis. In addition, RNA molecules may be modified to increase intracellular stabiUty and half-Ufe by addition of flanking sequences at the 5' and/or 3' ends of the molecule or by d e use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. Modification is inherent in the production of PNAs and can be extended to other derivative nucleotide molecules. Either the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, and/or the modification of adenine, cytidine, guanine, thymine, and uridine with acetyl-, methyl-, thio- groups renders the molecule less available to endogenous bacterial endonucleases. Screening Assays The M. catanhaUs nucleic acid molecule may be used to screen a pluraUty or a Ubrary of molecules or compounds for specific binding affinity. The molecules or compounds may be selected from aptamers, DNA molecules, RNA molecules, PNAs, peptides, transcription factors, enhancers, repressors, regulatory proteins and other ligands which modulate the activity, repUcation, transcription, or translation of the nucleic acid molecules in the biological system. The assay involves combining the M. catanhaUs nucleic acid molecule or a fragment thereof with molecules or compounds under conditions to allow specific binding, and detecting specific binding to identify at least one Ugand which specifically binds the M. catanhaUs nucleic acid molecule. Similarly the M. catanhaUs protein or a portion thereof may be used to screen a pluraUty of Ubraries of molecules or compounds in any of a variety of screening assays. The molecules or compounds may be selected from aptamers, DNA molecules, RNA molecules, peptide nucleic acids, peptides, mimetics, proteins, agonists, antagonists, antibodies, inhibitors, immunoglobulins, pharmaceutical agents, drug compounds, and the like. The protein or portion thereof employed in such screening may be free in solution, affixed to an abiotic or biotic substrate (eg, borne on a cell surface), or located intracellularly. Specific binding between the protein and molecule may be measured. One method for high throughput screening using very small assay volumes and very small amounts of test compound is described in USPN 5,876,946, incorporated herein by reference, which teaches how to screen large numbers of molecules for specific binding to a protein. Purification of Ligand The M. catanhaUs nucleic acid molecule or a fragment thereof may be used to purify a Ugand from a sample. A method for using a M. catanhaUs nucleic acid molecule or a fragment thereof to purify a ligand would involve combining the nucleic acid molecule or a fragment thereof with a sample under conditions to allow specific binding, detecting specific binding, recovering the bound M. catanhaUs nucleic acid molecule, and using an appropriate agent to separate the M. catanhaUs nucleic acid molecule from die purified ligand. Similarly, the protein or a portion thereof may be used to purify a ligand from a sample. A method for using a M. catanhaUs protein or a portion thereof to purify a Ugand would involve combining the protein or a portion thereof with a sample under conditions to allow specific binding, detecting specific binding between the protein and Ugand, recovering d e bound protein, and using an appropriate chaotropic agent to separate the protein from the purified ligand. Pharmacology Pharmaceutical compositions are those substances wherein d e active ingredients are contained in an effective amount to achieve a desired and intended purpose. The determination of an effective dose is well within the capabiUty of those skilled in the art. For any compound, the therapeutically effective dose may be estimated initially either in cell culture assays or in animal models. The animal model is also used to achieve a desirable concentration range and route of administration. Such information may then be used to determine useful doses and routes for administration in humans. A therapeutically effective dose refers to that amount of a pharmaceutical agent which ameUorates the symptoms or condition. Therapeutic efficacy and toxicity of such agents may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, eg, ED 50 (the dose therapeutically effective in 50% of the population) and LD 50 (the dose lethal to 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index, and it may be expressed as the ratio, LD 50 /ED 50 . Pharmaceutical compositions which exhibit large therapeutic indexes are prefened. The data obtained from cell culture assays and animal studies are used in formulating a range of dosage for human use. Rational Drug Design The goal of rational drug design is to produce structural analogs of biologically active M. catanhaUs proteins of interest or of ligands with which they interact. Any of these examples can be used to fashion drugs which are more active or stable forms of the protein, or which enhance or interfere with the function of a protein in vivo (Hodgson (1991) Bio/Technology 9:19-21). In one approach, the three-dimensional structure of an M. catanhaUs protein, or of an M. catanhaUs protein-inhibitor complex, is determined by X-ray crystallography, by computer modeUng or, most typically, by a combination of the two approaches. Both the shape and charges of the protein must be ascertained to elucidate die structure and to determine active site(s). Less often, useful information regarding the structure of a protein may be gained by modeUng based on the structure of homologous proteins. In both cases, relevant structural information is used to design analogous M. catanhaUs protein-Uke molecules or to identify efficient inhibitors. Useful examples of rational drug design may include molecules which have improved activity or stabiUty, as shown by Braxton et al. (1992, Biochem 31 :7796-7801), or which act as inhibitors, agonists, or antagonists of M. catanhaUs peptides, as shown by Athauda et al. (1993, J Biochem 113:742-746). It is also possible to isolate a target-specific antibody, selected by functional assay, as described above, and men to solve its crystal structure. This approach, in principle, yields a pharmacore upon which subsequent drug design can be based. It is possible to bypass protein crystallography altogether by generating anti-idiotypic antibodies (anti-ids) to a functional, pharmacologically-active antibody. As a minor image of a minor image, the binding site of the anti-id is an analog of the original receptor. The anti- id can be used to identify and isolate peptides from banks of chemically or biologically-produced peptides. The isolated peptides act as the pharmacore. EXAMPLES I Shotgun Sequencing Strategy The strategy for sequencing the M. catanhaUs genome was a modification of the shotgun approach to whole genome sequencing described by Lander and Waterman (1988 Genomics 2:231). They appUed the equation for the Poisson distribution p.=π e "m /x!, where x is the number of occunences of an event, m is d e mean number of occunences, and p x is the probability that any given base is not sequenced after a certain amount of random sequence has been generated. If L is the genome length, n is the number of clones insert ends sequenced, and w is the sequencing read length, then m=nw/L, and the probabiUty mat no clone originates at any of the w bases preceding a given base, ie, the probabiUty that a base is not sequenced, is p 0 =e 'm . For sequencing where Po>0, the total gap length is Le "m , and the average gap size is L/n. The shotgun approach has recentiy been used to sequence the genomes of H. influenzae (Fleischmann et al. (1995) Science 269:496; WO 96/33276), Mvcoplasma genitaUum (Fraser et al. (1995) Science 270:397 and Methanococcus jannashu (Bult et al. (1996) Science 273:1058). All of these microbes have relatively small genomes of 1.8, .6, and 1.8 megabases, respectively. The size of the M. catanhaUs genome is estimated to be 1.9 megabases. II Construction of the Genomic Library An M. catanhaUs genomic DNA Ubrary was constructed using DNA purified from the gram negative, aerobic diplococcus, M. catanhaUs. ATCC accession number 43617. The isolate was obtained from transtracheal aspirate of a coal miner with chronic bronchitis. The G+C content is 42%. Using a syringe fitted with a .0025 in. Ruby orifice (Stanford University, Stanford CA), 50 μg of M. catanhaUs DNA was sheared into 1.5-2.9 kb fragments. The shearing process was monitored by electrophoresis of a subsample of sheared DNA on a 0.8% SEAKEM GTG agarose gel (FMC Bioproducts, Rockland ME) in lxTAE buffer at about 950 V-h. Comparison with a DNA ladder with known size fragments was used to verify the size and quality of the sheared DNA Sheared DNA was visualized with low wavelength UV and bands of 1.5 to 2.8 kbs were removed from a preparative 0.8% SEAKEM GTG agarose gel (FMC Bioproducts). The 1.5-2.9 kb fragments were electrophoresced through a preparative 0.8% SEAPLAQUE GTG low melt agarose gel (FMC Bioproducts) in lxTAE buffer at about 850 V-h. The DNA band was removed from the low melt agarose, placed in an microcentrifuge tube, and the agarose melted at 65C for 10-15 minutes. After 5 minutes of heating, the melted agarose was diluted with a half volume of double distilled water, and the sample was equiUbrated to 42C. β-AGARASE (New England Biolabs (NEB), Beverly MA) and lOxβ-AGARASE (NEB) were added, and the preparation was incubated for 1-3 hours with addition of a half initial volume of β-AGARASE (NEB)after 1 hour and mixing by inversion every half hour. The DNA was extracted once with phenol:chloroform:isoamyl alcohol (25:24:1) followed by extraction with chloroform:isoamyl alcohol (24:1) and precipitated by addition of 1-3 μl glycogen, 1/10 volume 3M NaOAc, and 2.5 volumes cold 100% ethanol. The sample was stored overnight at -20C. The purified DNA strands were treated with BAL31 (NEB) at 1U/20 μg DNA in a final volume of 50 μl at 30C for 10 minutes to prepare blunt ends. Then the DNA was re-extracted as above (phenol:chloroform:isoamyl alcohol followed by chloroform:isoamyl alcohol). The DNA was reprecipitated as above and stored at -20C until Ugation into the vector. The PBLUESCRIPT plasmid (Stratagene) was cut with Smal endonuclease, and the ends of the strands dephosphorylated to prepare the BS.S2 vector. The purified M. catanhaUs DNA (2 μg) was Ugated into the BS.S2 vector (1 μg) with T4 DNA Ugase (Life Technologies) for 4 hours at 14C. Following the Ugation reaction, the ligated DNA was extracted and precipitated as above. The Ugated vectoπinsert DNA was the size selected (vector + insert = 4.4-5.7 kb) and purified by gel electrophoresis and extracted as described above. Following gel purification, the ends of the vector:insert DNA were repaired using T4 DNA polymerase (NEB) for 5 minutes at 37C, re-extracted and precipitated as above, and self-Ugated into circles with T4 DNA ligase (Life Technologies). After 10 minutes, the Ugation reaction was stopped by heating at 70C for 10 minutes. The circular plasmid was transformed into DH10B competent cells (Life Technologies) by electroporation at 1.8 volts. Transformed cells were selected by growth on X-Gal+isopropyl beta-D- thiogalactopyranoside (IPTG)+2x carbenicilUn (carb) LB agar plates. III Isolation of Clones and Sequencing Plasmid DNA was released from the cells and purified using the REAL PREP 96 plasmid kit (QIAGEN, Chatsworth CA). This kit enabled simultaneous purification of 96 samples in a 96-well block using multi-channel reagent dispensers. The recommended protocol was employed except for the following changes: 1) the bacteria were cultured in 1 ml of sterile TERRIFIC BROTH (BD Biosciences, Sparks MD) with carb at 25 mg/1 and glycerol at 0.4%; 2) after inoculation and incubation for 19 hours, the cells were lysed with 0.3 ml of lysis buffer; and 3) following isopropanol precipitation, the plasmid DNA pellet was resuspended in 0.1 ml of distilled water. After this final step, samples were transferred to a 96-well block for storage at 4C. The DNA inserts were prepared for sequencing using a 96 well HYDRA microdispenser (Robbins Scientific) in combination with DNA ENGINE thermal cyclers (MJ Research). After thermal cycUng, the A, C, G, and T reactions with each DNA template were combined. Then, 50 μl 100% ethanol was added, and the solution was spun at 4C for 30 min at 4500 rpm in a centrifuge (Jouan, Winchester VA). After the pellet was dried for 15 min under vacuum, the DNA sample was dissolved in 3 μl of formaldehyde/50 mM EDTA and loaded on wells in volumes of 1 μl per well for sequencing. Sequencing used the method of Sanger and Coulson (1975, J. Mol. Biol. 94:441f) and an ABI PRISM 377 sequencing systems (PE Biosystems). After electrophoresis for four hours on 4% acrylamide gels on 36 cm plates at 2.3 kV, approximately 500-650 bps were determined per sequence. IV Sequence Processing and Contiguous Sequence Assembly Sequences were generated from either shotgun sequencing or closure sequencing. Closure sequences were obtained by directed genomic walks or PCR of specific genomic regions. In the latter case, the PCR products were sequenced. Sequences were edited in a two-step process. In the first step, vector sequences from both the 5' and 3' ends were clipped using the algorithm provided in USSN 09/276,534 filed 25 March 1999. In the second step, possible contaminating sequence was removed by reading each raw sequence and performing a cross- match search against a contamination database containing known vector sequences and DNA marker sequences. Sequences with cross-match scores of 18 or greater were removed. Contigs were assembled using PHRAP (Green, supra) which aUgns multiple, overlapping DNA sequences to form a contiguous consensus sequence. AUgnments were influenced by quaUty scores assigned to each base in a sequence. A single sequence cannot belong to more than one contig. The 41 contigs presented in Table 1 and the Sequence Listing were assembled from 47385 individual sequences. The contigs represent approximately 13.3x coverage or 100.7% of the M. catanhaUs genome. V Gene Finding ORF identification was canied out through combination of BLAST (KarUn, supra) and FASTA searches. These serial searches compared the consensus sequences of the assembled contigs, presented in Table 1, against sequences in public-domain databases. The searches identified similarity matches, or "hits", that indicated an ORF within the sequence. The consensus sequences of die contigs were analyzed against the GenBank peptide (GenPept) database. The ORF identification process assigned ORFs to loci on a contig. If a match was found at a P- value less than or equal to le-6, the conesponding locus on the contig was designated as an ORF. This portion of the contig was masked by Ns, and the consensus sequence underwent a second BLASTX or FASTX search against the GenPept database. Again, the match with the lowest P- value (less than or equal to le-6) was used to identify a second ORF. The conesponding sequences were masked, and the process continued until all BLASTX and FASTX matches with P- values less than or equal to le-6 had been identified for a given contig. Then, the contigs were run through GeneMark, an algorithm for identifying putative ORFs. The GeneMark algorithm is described and developed in the following references: Borodovsky and Mclninch (1993) Computers & Chemistry 17:123; Blattner et al. (1993) Nucl Acid Res 21 :5408; and Borodovsky et al.(1994) Trends Biochem Sci 19:309. After all possible homology and algorithm-based ORFs were identified, a process called ORF selection was appUed. In this process GeneMark ORFs that overlapped homology-based ORFs were rejected, and homology-based ORFs were retained. GeneMark ORFs that did not overlap homology-based ORFs and those that overlapped other GeneMark ORFs were retained. Finally, all ORFs were annotated by performing BLAST2 comparisons against GenPept and taking annotation from the best hit with P- value less than or equal to le-6. Contigs with high probabiUty for ORFs, but no identified ORFs, were identified as "orphan" contigs (Table 1). Unannotated regions of contigs exceeding 500 bases in length were identified as "Long- Unannotated Regions" Q_URs) and contain novel ORFs. The designations, orphan and LUR, were based on comparative analyses of the lengths of ORFs and unannotated regions. A total of 1258 ORFs were identified by homology searches of the GenPept database with an additional 253 ORFs identified using the GeneMark algorithm. VI Gene Clustering In the final step of analysis, a gene clustering protocol is used to determine related ORFs within and across genomes. Gene clustering is canied out through BLAST2 pairwise comparisons of each ORF in the PATHOSEQ database (Incyte Genomics, Palo Alto CA) against every other ORF in the database. If two ORFs matched each other at a P- value less than or equal to le-15, they were placed in the same cluster. If a third ORF matched either of the first two ORFs at a P- value of less than or equal to le-15, the third ORF joined the cluster. Thus, clusters were formed so that any ORF in a cluster must match at least one other ORF in the cluster at less than or equal to the threshold P- value of le-15. The representative ORF for a cluster is the one with the best matched annotation. VII Ordering of Contiguous Sequences The ordering of contigs has been accompUshed through three types of analyses: 1) 573' sequence pair information, 2) annotation information, and 3) BLAST2 analysis of the ends of contigs. Contig ordering based on 573' sequence pairs was done by identifying all 573' sequence pairs (5' and 3' sequences with the same Sequence ID) that were not in the same contig, but span a gap between two contigs with the estimated distance between them of about 1.5-3.0 kb (the insert size of the Ubrary). Annotation information was used to determine contig order in two ways, either by identifying genes spanning contig gaps or by comparison with genes at the ends of contigs in related organisms with similar gene order. Genes spanning gaps were identified by observing the N-terminal portion of an ORF at the end of one contig and the C-terminal portion of an ORF at the end of another contig. Two partial ORFs are considered to be portions of the same ORF when they meet this criteria and annotate to the same top five GenPept database entries. Comparison of two related organisms with similar gene order is used to predict contig ordering when one organism contains continuous gene order information over a region that spans a gap in d e second organism. BLAST analysis of the ends of contigs was used to identify those contigs which overlapped, but failed to join because the sequence overlap did not meet the length or quaUty score required by PHRAP (Green, supra). Table 2 shows the ordering of the M. catanhaUs contigs as supported by one or more of these analyses. VIII Extension of Partial ORFs to Full Length Using the DNA sequences disclosed herein, an ORF is extended using a modified XL-PCR (PE Biosystems) procedure. OUgonucleotide primers, one to initiate 5' extension and the other to initiate 3' extension were designed using the nucleotide sequence of the known fragment and OLIGO 4.06 software (National Biosciences). The initial primers were about 22 to 30 nucleotides in length, had a GC content of about 42%, and annealed to the target sequence at temperatures of about 55C to about 68C. Any fragment which would result in hairpin structures and primer-primer dimerizations was avoided. The genomic DNA Ubrary was used to extend the molecule. If more than one extension was needed, additional or nested sets of primers were designed. High fideUty ampUfication was obtained by performing PCR in 96-well plates using the DNA ENGINE thermal cycler (MJ Research). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing Mg 2+ , (NH 4 ) 2 SO 4 , and β-mercaptoethanol, Taq DNA polymerase (APB), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair selected from the plasmid: Step 1 : 94C, 3 min; Step 2: 94C, 15 sec; Step 3: 60C, 1 min; Step 4: 68C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68C, 5 min; Step 7: storage at 4C. In the alternative, parameters for the primer pair, T7 and SK+ (Stratagene), were as follows: Step 1 : 94C, 3 min; Step 2: 94C, 15 sec; Step 3: 57C, 1 min; Step 4: 68C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68C, 5 min; Step 7: storage at 4C. The concentration of DNA in each well was determined by dispensing 100 μl PICOGREEN quantitation reagent (0.25% v/v; Molecular Probes) dissolved in lxTE and 0.5 μl of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar, Acton MA) and allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II (Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the concentration of DNA A 5 μl to 10 μl aliquot of die reaction mixture was analyzed by electrophoresis on a 1% agarose mini-gel to determine which reactions were successful in producing longer sequence. The extended sequences were desalted, concentrated, transfened to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WT), and sonicated or sheared prior to reUgation into pUC18 vector (APB). For shotgun sequencing, d e digested fragments were separated on about 0.6-0.8% agarose gels, fragments were excised as visuaUzed under UV Ught, and agarose removed/digested with AGARACE enzyme 0?romega). Extended fragments were reUgated using T4 DNA Ugase (NEB) into pUC18 vector (APB), treated with Pfu DNA polymαase (Stratagene) to fill-in restriction site overhangs, and transformed into competent E. coji cells. Transformed cells were selected on antibiotic- containing media, and individual colonies were picked and cultured overnight at 37C in 384-well plates in LB/2x carb Uquid media. The cells were lysed, and DNA was amplified using Taq DNA polymerase (APB) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1 : 94C, 3 min; Step 2: 94C, 15 sec; Step 3: 60C, 1 min; Step 4: 72C, 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72C, 5 min; Step 7: storage at 4C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries were reamplified using the conditions described above. Samples were diluted with 20% dimethysulphoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (APB) or the ABI PRISM BIGDYE terminator kit Q?E Biosystems). IX Labeling of Probes and Hybridization Analyses Substrate Preparation Nucleic acids are isolated from a biological source and appUed to a substrate for standard hybridization protocols by one of the following methods. A mixture of nucleic acids, a restriction digest of genomic DNA, is fractionated by electrophoresis through an 0.7% agarose gel in lxTAE running buffer and transfened to a nylon membrane by capillary transfer using 20x saUne sodium citrate (SSC). Alternatively, e nucleic acids are individually Ugated to a vector and inserted into bacterial host cells to form a Ubrary. Nucleic acids are ananged on a substrate by one of the following methods. In the first method, bacterial cells containing individual clones are robotically picked and ananged on a nylon membrane. The membrane is placed on bacterial growth medium, LB agar containing carb, and incubated at 37C for 16 hours. Bacterial colonies are denatured, neutraUzed, and digested with proteinase K. Nylon membranes are exposed to UV inadiation in a STRATALINKER UV-crossUnker (Stratagene) to cross-Unk DNA to the membrane. In the second method, nucleic acids are ampUfied from bacterial vectors by thirty cycles of PCR using primers complementary to vector sequences flanking the insert. AmpUfied nucleic acids are purified using SEPHACRYL-400 beads (APB). Purified nucleic acids are robotically anayed onto a glass microscope sUde (Corning Science Products, Corning NY). The slide is previously coated with 0.05% aminopropyl silane (Sigma-Aldrich, St. Louis MO) and cured at 1 IOC. The anayed glass slide (microanay) is exposed to UV inadiation in a STRATALINKER UV-crossUnker (Stratagene). Probe Preparation DNA probes are made from mRNA templates. Five micrograms of mRNA is mixed with 1 μg random primer (Life Technologies), incubated at 70C for 10 minutes, and lyophilized. The lyophiUzed sample is resuspended in 50 μl of lx first strand buffer (cDNA Synthesis systems; Life Technologies) containing a dNTP mix, [α- 32 P]dCTP, dithiothreitol, and MMLV reverse tianscriptase (Stratagene), and incubated at 42C for 1-2 hours. After incubation, the probe is diluted with 42 μl dH 2 O, heated to 95C for 3 minutes, and cooled on ice. mRNA in the probe is removed by alkaUne degradation. The probe is neutraUzed, and degraded mRNA and unincorporated nucleotides are removed using a PROBEQUANT G- 50 column (APB). Probes are labeled with fluorescent markers, Cy3-dCTP or Cy5-dCTP (APB), in place of the radionucleotide, [ 32 P]dCTP. Hybridization Hybridization is canied out at 65C in a hybridization buffer containing 0.5 M sodium phosphate (pH 7.2), 7% SDS, and 1 mM EDTA After the substrate is incubated in hybridization buffer at 65C for at least 2 hours, the buffer is replaced with 10 ml of fresh buffer containing the probes. After incubation at 65 C for 18 hours, the hybridization buffer is removed, and the substrate is washed sequentially under increasingly stringent conditions, up to 40 mM sodium phosphate, 1% SDS, 1 mM EDTA at 65C. To detect signal produced by a radiolabeled probe hybridized on a membrane, the substrate is exposed to a PHOSPHORIMAGER cassette (APB), and the image is analyzed using IMAGEQUANT data analysis software (APB). To detect signals produced by a fluorescent probe hybridized on a microanay, the substrate is examined by confocal laser microscopy, and images are collected and analyzed using GEMTOOLS gene expression analysis software (Incyte Genomics). X Complementary Nucleic Acid Molecules Molecules complementary to the nucleic acid molecule, or a fragment thereof, are used to detect, decrease, or inhibit gene expression. Although use of oUgonucleotides comprising from about 15 to about 30 base pairs is described, the same procedure is used with larger or smaller fragments or derivatives such as peptide nucleic acids 0?NAs). OUgonucleotides are designed using OLIGO 4.06 software (National Biosciences) and a nucleic acid molecule of the Sequence Listing or fragment thereof. To inhibit transcription by preventing promoter binding, a complementary oUgonucleotide is designed to bind to sequence 5 ' of the ORF, most preferably about 10 nucleotides before the initiation codon of the ORF. To inhibit translation, a complementary oUgonucleotide is designed to prevent ribosomal binding to the mRNA encoding the M. catanhaUs protein. XI Expression of an M. catarrhalis Protein An M. catanhaUs nucleic acid molecule is subcloned into a vector containing an antibiotic resistance gene and the inducible T5 or T7 bacteriophage promoter in conjunction with the lac operator regulatory element. Recombinant vectors are transformed into BL21(DE3) competent cells (Stratagene). Antibiotic resistant bacteria express the bacterial protein upon induction with IPTG. The protein is synthesized as a fusion protein with FLAG which permits affinity-based purification of the recombinant fusion protein from crude cell lysates. Kits for immunoaffinity purification using monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak, Rochester NY) are commercially available. Following purification the heterogeneous moiety is proteolytically cleaved from the bacterial protein at specifically engineered sites. Purified protein is used directly in the production of antibodies or in activity assays. XII Production of M. catarrhalis Protein Specific Antibodies An M. catarrhaUs produced as described above or an oUgopeptide designed and synthesized using an ABI 431 A peptide synthesizer (FΕ Biosystems) is used to produce an antibody. Animals are immunized with the protein or an oUopeptide-KLH complex in complete Freund's adjuvant. Immunizations are repeated at intervals thereafter in incomplete Freund's adjuvant. After a mimmum of seven weeks for mouse or twelve weeks for rabbit, antisera are drawn and tested for antipeptide activity. Testing involves binding the peptide to plastic, blocking with 1% bovine serum albumin, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG. Methods and machinery well known in the art are used to determine antibody titer and the amount of complex formation. XIII Screening or Purifying Molecules Using Specific Binding The nucleic acid molecule, or fragments thereof, or the protein, or portions thereof, are labeled with 32 P-dCTP, Cy3-dCTP, Cy5-dCTP (APB), or BIODIPY or FITC (Molecular Probes), respectively. Libraries of candidate molecules previously ananged on a substrate are incubated in the presence of labeled nucleic acid molecule or protein. After incubation under conditions for either a nucleic acid or amino acid sequence, the substrate is washed, and any position on the substrate retaining label, which indicates specific binding or complex formation, is assayed, and the binding molecule is identified. Data obtained using different concentrations of the nucleic acid or protein are used to calculate affinity between the labeled nucleic acid or protein and the bound molecule. XIV Identification of M. catarrhalis Genes Induced During Infection In vivo expression technology (IVET) is used with the sequences, or ORFs, to identify M. catanhaUs genes specifically induced during infection or under pathogenic conditions (Mahan et al. (1993) Science 259:686). A Ubrary of random genomic fragments of M. catarrhalis is made and Ugated to a gene for a selectable marker required for survival in die host animal. Only those M. catanhaUs cells harboring a fusion sequence containing an active promoter will survive passage through the host. Fusion bearing promoters with constitutive activity are identified and discarded by examining reporter activity on laboratory medium passaged M- catanhaUs bacteria. By harvesting M. catanhaUs cells from infection sites in the host and subtraction of the identified constitutively activated genes, a Ust of genes turned on during infection or under pathogenic conditions are compiled. Host induced M. catanhaUs genes are identified using the M. catanhaUs sequences and ORFs disclosed herein and the method of differential fluorescence induction described by Valdivia and Falkow (1996; Mol Microbiol 22:367). XV Identification of M. catarrhalis Genes Required for Survival in Host Using the M. catanhaUs genomic sequences and ORFs, genes required for survival in a host is determined using the signature-tagged transposon method described by Hensel et al. (1995; Science 269:400). A Ubrary of M. catanhaUs mutants is marked with a unique oligonucleotide sequence for each disrupted gene. After passage of the Ubrary though an infected animal or other selective environment, putative survival genes are identified by absence of the mutant from the passaged Ubrary. Various modifications of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been describes specific prefened embodiments, it should be understood that the invention as claimed should not be unduly Umited to such specific embodiments. Indeed, various modifications of the above-described modes for canying out the invention which are obvious to those skilled in the field of molecular biology or related fields are intended to be within the scope of the following claims. TABLE 1 TABLE

Claims: CLAIMS 1. A Moraxella catarrhaUs genomic Ubrary comprising the combination of nucleic acid molecules or their complements shown in the Sequence Listing as SEQ ID NOs: 1-41. 2. A method of identifying diagnostic compositions comprising comparison of the Ubrary of claim 1 to nucleic acid molecules of other organisms. 3. A method of identifying diagnostic compositions, the method comprising: a) using the method of claim 2, and b) computer databases to make the comparison. 4. A method of identifying therapeutic compositions comprising comparison of the Ubrary of claim 1 to nucleic acid molecules of other organisms. 5. A method of identifying therapeutic compositions, the method comprising: a) using the method of claim 4, and b) computer databases to make the comparison. 6. A purified M. catarrhaUs nucleic acid molecule or a fragment thereof comprising a nucleic acid sequence on a contiguous sequence contained within the library of claim 1. 7. An expression vector containing the nucleic acid molecule of claim 6. 8. A host cell containing the expression vector of claim 7. 9. A method for producing an M. catarrhaUs protein, the method comprising: a) culturing the host cell of claim 8 under conditions for expression of the M. catarrhalis protein; and b) recovering the protein from cell culture. 10. A purified M. catarrhaUs protein or a portion thereof comprising a protein encoded by a nucleic acid molecule on a contiguous sequence contained within the M. catarrhaUs genomic Ubrary of claim 1. 11. A method for using an M. catarrhaUs protein to screen a pluraUty of molecules or compounds to identify at least one ligand which specifically binds the protein, the method comprising: a) combining the protein of claim 10 with the Ubrary of molecules or compounds under conditions to allow specific binding, and b) detecting specific binding, thereby identifying a Ugand which specifically binds the protein. 12. The method of claim 11 wherein the molecules or compounds are selected from aptamers, DNA molecules, RNA molecules, peptide nucleic acids, peptides, mimetics, proteins, agonists, antagonists, antibodies, immunoglobuUns, inhibitors, pharmaceutical agents, and drug compounds. 13. A method of using an M. catarrhalis protein to purify a Ugand from a sample, the method comprising: a) combining the protein of claim 10 with the sample under conditions to allow specific binding, b) detecting specific binding between the protein and a Ugand, c) recovering the bound protein, and d) separating the protein from the ligand, thereby obtaining purified Ugand. 14. A method of using an M. catarrhalis nucleic acid molecule to screen a pluraUty of molecules or compounds to identify at least one Ugand which specifically binds the nucleic acid molecule, the method comprising: a) combining the nucleic acid molecule of claim 6 with molecules or compounds under conditions to 5 allow specific binding, and b) detecting specific binding, thereby identifying a Ugand which specifically binds the nucleic acid molecule. 15. The method of claim 14 wherein the Ubrary is selected from aptamers, DNA molecules, RNA molecules, peptide nucleic acids, peptides, transcription factors, enhancers, repressors and regulatory proteins. 10 16. A probe comprising the nucleic acid molecule of claim 6. 17. A method for detecting an M. catarrhaUs nucleic acid molecule in a sample, the method comprising the steps of: a) hybridizing the probe of claim 16 to at least one nucleic acid in the sample, thereby forming a hybridization complex; and 15 b) detecting the hybridization complex, wherein the presence of the hybridization complex indicates the presence of the M. catarrhalis nucleic acid molecule in the sample. 18. The method of claim 17 further comprising amplifying the nucleic acids of the sample prior to hybridization.

Inventors: BERG KIM L, LAGACE ROBERT E, PATTERSON CHANDRA, BERG, KIM, L., LAGACE, ROBERT, E., PATTERSON, CHANDRA
Applicants: BERG KIM L, INCYTE GENOMICS INC, LAGACE ROBERT E, PATTERSON CHANDRA, BERG, KIM, L., INCYTE GENOMICS, INC., LAGACE, ROBERT, E., PATTERSON, CHANDRA
Application year: 2000
Main classification: C12N15
IPC codes: C07K14, C12N15